在转换生物类似药和参考生物药时的安全结果:系统性审查和元分析
Thomas M Herndon1, Cristina Ausin1, Nina N Brahme1
1Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
将患者从参考生物制剂转换为生物仿制药是安全的. 一项系统性审查发现,当患者切换治疗时,安全性或免疫性没有显著差异,支持生物类似药的采用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 生物仿制药为治疗严重疾病提供了替代方案.
- 对于将患者从参考生物制剂转换为生物仿制药存在担忧.
研究的目的:
- 系统地审查和统计分析患者在参考生物药物和生物类似药物之间切换的安全性和免疫性.
主要方法:
- 从FDA数据和同行评审的出版物中确定了随机对照和扩展研究,其中包括切换治疗周期 (STP).
- 根据PRISMA指导方针,从44个STP中提取和综合了21种生物类似药的31项研究中的数据.
- 对5,252名患者进行了元分析,以评估风险差异.
主要成果:
- 切换和非切换患者之间在安全结果 (死亡,严重不良事件,中止) 中没有显著差异.
- 在切换患者和未切换患者中,抗药抗体和中和抗体的发病率相似.
- 在两组中,免疫相关的不良事件 (过敏反应,过敏症) 的比率相似.
结论:
- 在基准生物药和生物类似药之间切换患者不会改变安全性或免疫性.
- 研究结果支持在临床实践中安全使用生物仿制药,即使有治疗切换.
更多相关视频
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioequivalence: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Biopharmaceutics and Pharmacokinetics: Overview
Comparing the Survival Analysis of Two or More Groups
